Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Change in Acquisitions & Divestments (2021 - 2025)

Krystal Biotech's Change in Acquisitions & Divestments history spans 5 years, with the latest figure at $85.8 million for Q4 2025.

  • For Q4 2025, Change in Acquisitions & Divestments rose 41.77% year-over-year to $85.8 million; the TTM value through Dec 2025 reached $375.6 million, up 25.83%, while the annual FY2025 figure was $375.6 million, 25.83% up from the prior year.
  • Change in Acquisitions & Divestments for Q4 2025 was $85.8 million at Krystal Biotech, down from $95.8 million in the prior quarter.
  • Across five years, Change in Acquisitions & Divestments topped out at $161.2 million in Q2 2023 and bottomed at $1.2 million in Q2 2021.
  • The 5-year median for Change in Acquisitions & Divestments is $76.9 million (2023), against an average of $73.4 million.
  • The largest annual shift saw Change in Acquisitions & Divestments surged 4992.62% in 2022 before it tumbled 58.83% in 2024.
  • A 5-year view of Change in Acquisitions & Divestments shows it stood at $21.0 million in 2021, then surged by 395.73% to $104.1 million in 2022, then decreased by 28.33% to $74.6 million in 2023, then dropped by 18.9% to $60.5 million in 2024, then soared by 41.77% to $85.8 million in 2025.
  • Per Business Quant, the three most recent readings for KRYS's Change in Acquisitions & Divestments are $85.8 million (Q4 2025), $95.8 million (Q3 2025), and $105.3 million (Q2 2025).